Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. As President Trump hails ...

Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, The Readout Loud.

Lizzi C. Lee is a fellow on the Chinese economy at Asia Society Policy Institute’s Center for China Analysis (CCA), based in Washington DC, USA. Jing Qian is vice-president of the Asia Society and ...

Heavyweight European venture capital firms like Novo Holdings and Sofinnova Partners have joined together to make the case for more urgently needed funding in the continent's biotech ecosystem. The ...

Welcome to Fierce Biotech's fifth annual layoff tracker, a resource designed to keep pace with the sector's steady stream of workforce reductions. In 2025, industry layoffs continued to rise year over ...

Goldman Sachs believes that Biohaven offers investors an under-the-radar opportunity to invest in a potentially best-in-class kidney disease treatment. The bank initiated coverage on the ...

Eli Lilly has struck a deal to buy genetic-medicine biotechnology company Orna Therapeutics for up to $2.4 billion in cash. Eli Lilly on Monday said Orna, which is dedicated to engineering immune ...

Recursion Pharmaceuticals crashed 90% but JPMorgan upgraded with $11 target implying near tripling. Eli Lilly partnered with Nvidia on a $1B AI drug discovery collaboration using Vera Rubin chips.

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Eli Lilly and Co. is buying a ...

Krystal Biotech (KRYS) announced on Monday that the U.S. Food and Drug Administration awarded the Regenerative Medicine Advanced Therapy designation for KB707, its immunotherapy candidate targeting ...

HONG KONG/SHANGHAI, Feb 13 (Reuters) - Global drugmakers are stepping up their search for China‑developed experimental medicines as they cut costs ahead of patent expirations, with industry analysts ...